Arvinas to Present at Upcoming Investor Conferences
31 août 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Changes to its Board of Directors
18 août 2022 16h01 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations
15 août 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
04 août 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Appoints John Northcott as Chief Commercial Officer
01 août 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
02 juin 2022 16h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
01 juin 2022 08h00 HE
|
Arvinas Inc.
-- In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation – --...
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update
05 mai 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Bank of America Securities 2022 Healthcare Conference
03 mai 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Upcoming Investor Conferences
04 mars 2022 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...